Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2017

Supporting information for

A Mild Two-Step Propargylation of

Aromatic Bioactive Small Molecules

Naoki Kanoh, Toshitaka Okamura, Takahiro Suzuki, and Yoshiharu Iwabuchi

Graduate School of Pharmaceutical Sciences, Tohoku University, Aobayama, Sendai 980-8578, Japan

Table of Contexts

1.	General procedure		1
2.	Synthesis of complex 1a		2
3.	Synthesis of ammonium com	plex S2	2
4.	Preparation of substrate 10		3
5.	Functionalization of aromatic	bioactive small molecules	3
6.	Decomplexation of dicobalt h	exacarbonyl complexes	12
7.	References		18
8.	¹ H-NMR Comparison of aron hexacarbonyl complexes	natic bioactive small molecules and their dicobalt	19
9.	NMR spectra		32

1. General procedure

All reactions were carried out under an argon atmosphere with dehydrated solvents under anhydrous conditions, unless otherwise noted. Dehydrated THF and CH₂Cl₂ were purchased from Kanto Chemical Co., Inc. Other solvents were dehydrated and distilled according to standard protocols. Reagents were obtained from commercial suppliers, unless otherwise noted. Reactions were monitored by thin-layer chromatography (TLC) carried out on Silica gel plates (Merck). Column chromatography was performed on Silica gel 60N (Kanto Chemical Co., Inc., spherical, neutral, 63-210 µm) or (Kanto Chemical Co., Inc., spherical, neutral, 40-50 µm). High performance column chromatography was performed on Mightysil Si60 250-20 mm (Kanto Chemical Co., Inc., spherical, neutral, 5 µm). IR spectra were recorded on a JASCO FT/IR-410 Fourier Transform Infrared Spectrophotometer. ¹H-NMR (400 and 600 MHz) and ¹³C-NMR spectra (100 and 150 MHz) were recorded on JEOL JNM-AL-400 and JEOL JNM-ECA-600 spectrometers, respectively. For ¹H-NMR spectra. chemical shifts (δ) are given from TMS (0.00 ppm) or CHCl₃ (7.26 ppm) in CDCl₃, CHD₂COCD₃ (2.05 ppm) in CD₃COCD₃ and CHD₂SOCD₃ (2.50 ppm) in CD₃SOCD₃ as internal standards. For ¹³C-NMR spectra, chemical shifts (δ) are given from CDCl₃ (77.0 ppm), CD₃COCD₃ (29.84 ppm and 206.26 ppm) and CD₃SOCD₃ (39.52 ppm) as internal standards. The following abbreviations were used to explain the multiplicities: s = singlet, d =doublet, t = triplet, q = quartet, dd, = double doublet, ddt = double double triplet, m =multiplet, br = broad. EI mass spectra were recorded on JEOL JMS-DX303, JEOL JMS-700 and JEOL JMS-T 100 GC. FAB mass spectra were recorded on JEOL JMS-700. ESI mass spectra were recorded on Thermo Scientific Exactive Mass Spectrometer. HPLC was performed on Gilson Model 305 and 306 as pumps and Gilson Model 118 as a UV detector (254 nm) using Mightysil Si60 \u03c620-250 mm (Kanto Chemical Co., Inc., spherical, neutral, 5 um).. Microwave irradiation was performed by using a DiscoverTM system (CEM Japan Inc).

2. Synthesis of complex 1a Synthesis of (prop-2-yn-1-ol)dicobalt hexacarbonyl (S1)¹



A mixture of prop-2-yn-1-ol (0.90 mL, 15.6 mmol) and $Co_2(CO)_8$ (5.22 g, 15.6 mmol) in CH_2Cl_2 (38 mL) was stirred at room temperature for 5 h. The solution was concentrated in vacuo. Column chromatography of the residue on silica gel (EtOAc / Hexane = 1 / 4) yielded cobalt complex **S1**¹ as a red solid (4.76 g, 13.9 mmol, 93%).

Synthesis of hexacarbonyl(2-propynylium)dicobalt tetrafluoroborate (1a)¹



To a solution of HBF₄•Et₂O (1.10 mL, 6.99 mmol) in Et₂O (6.0 mL) was added a solution of cobalt complex **S1** (798 mg, 2.33 mmol) in Et₂O (5.5 mL) dropwise over 15 min. The resulting mixture was stirred at room temperature for 2 h, causing precipitation of a red solid. The solid was filtered and rinsed three times with ether to remove fluoroboric acid. After vacuum drying, complex $1a^1$ was obtained as a fine red powder (828 mg, 2.01 mmol, 86%).

3. Synthesis of ammonium complex S2



To a suspension of complex **1a** (100 mg, 0.243 mmol) in CH_2Cl_2 (4.0 mL) was added Et_3N (2.0 ml). The reaction mixture was stirred at room temperature for 1 h and then concentrated in vacuo. The residue was purified by silica gel column chromatography (MeOH : $CHCl_3 = 1 : 4$) to give complex **S2** (74.5 mg, 0.145 mmol, 60%) as a red amorphous.

S2: red amorphous; IR (neat): 2055 cm⁻¹; ¹H-NMR (400 MHz, CD₃COCD₃): δ 7.06 (s, 1H), 5.22 (s, 2H), 3.69 (q, J = 7.1 Hz, 6H), 1.47 (t, J = 7.1 Hz, 9H); ¹³C-NMR (100 MHz, CD₃COCD₃): δ 199.7, 77.2, 75.7, 60.6, 53.6, 8.1; HRMS (ESI): calcd for C₁₅H₁₈NO₆Co₂ (M⁺): 425.9793, found: 425.9778.

4. Preparation of substrate 10



To a solution of carbamate $S3^2$ (1.00 g, 3.17 mmol) in THF (16 mL) was added 60% NaH (387 mg, 9.68 mmol) at 0 °C and the resulting mixture was stirred for 30 min at room temperature. Then the reaction mixture was cooled at 0 °C and MeI (0.5 mL, 0.80 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred for 3.5 h. The reaction was quenched with sat. NH₄Cl (5 mL) and extracted with Et₂O (20 ml × 2). The combined organic layers were washed with brine, dried over Mg₂SO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (AcOEt : Hexane = 1:1) to give **10** (998 mg, 3.03 mm, 95%) as a yellow oil.

10: yellow oil; IR (neat): 1701 cm⁻¹; ¹H-NMR (400 MHz, CD₃SOCD₃): δ 7.37-7.29 (m, 5H), 6.84 (d, *J* = 8.0 Hz, 1H), 6.77 (d, *J* = 1.7 Hz, 1H), 6.79 (dd, *J* = 8.0 Hz, 1.7 Hz, 1H), 5.04 (s, 2H), 3.73 (s, 3H), 3.72 (s, 3H), 3.46 (t, *J* = 7.2 Hz, 2H), 2.83 (s, 3H), 2.73 (t, *J* = 7.2 Hz, 2H); ¹⁹C-NMR (100 MHz, CD₃SOCD₃): δ 154.9, 148.8, 147.4, 136.7, 131.4, 127.7, 127.1, 126.8, 120.4, 113.3, 112.7, 65.6, 55.6, 55.5, 49.5, 33.7, 32.6; HRMS (ESI): calcd for C₁₉H₂₃NO₄Na ([M+Na]⁺): 352.1519, found 352.1505.

5. Functionalization of aromatic bioactive small molecules

General procedure for the functionalization of aromatic bioactive small molecules

Procedure A: To a suspension of complex **1a** (0.150 mmol) and Cs_2CO_3 (1.0 mmol) in CH_2Cl_2 (1.0 mL) was added neat substrate (0.100 mmol) or a solution of substrate (0.100 mmol) in CH_2Cl_2 (1.0 mL) at -20 °C or 0 °C. The solution was allowed to warm to 0 °C or room temperature and stirred until completion of the reaction as monitored by TLC. The reaction mixture was diluted with water (2.0 mL) and extracted with CH_2Cl_2 (4.0 mL × 2). The combined organic layers were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography or HPLC.

Procedure B: The suspension of complex **1a** (0.150 mmol), Cs_2CO_3 (0.100 mmol) and substrate (0.100 mmol) in CH₂Cl₂ (2.0 mL) was heated at 40 °C by microwave irradiation. After reaction was complete, the mixture was diluted with water (2.0 mL) and extracted with CH₂Cl₂ (4.0 mL × 2). The combined oragnic layers were dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography.

Functionalization of estrone 3-methyl ether (2)



The procedure A was followed with a reaction time of 30 min at room temperature to provide a mixture (57.8 mg) of **3** (0.0451 mmol, 45%), **4** (0.0397 mmol, 40%) and **5** (6.60 μ mol, 7%). The product ratio was determined by ¹H-NMR. The analytical samples were obtained by HPLC separation (AcOEt : Hexane = 15 : 85, 9 mL/min).

3 (retention time: 13.5 min): red oil; IR (neat): 2018 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): . δ 7.07 (s, 1H), 6.57 (s, 1H), 6.00 (s, 1H), 4.07 (s, 2H), 3.79 (s, 3H), 2.89-2.86 (m, 2H), 2.50 (dd, *J* = 19.1 Hz, 8.5 Hz, 1H), 2.40-2.37 (m, 1H), 2.23-1.95 (m, 4H), 1.64-1.36 (m, 6H), 0.91 (s, 3H); ¹³C-NMR (100 MHz, CDCl₃): δ 221.0, 199.9, 155.0, 136.4, 131.5, 127.6, 126.0, 110.6, 98.4, 73.7, 54.8, 50.4, 48.0, 43.8, 38.4, 35.9, 33.9, 31.6, 29.6, 26.6, 25.8, 21.6, 13.8; HRMS (ESI): calcd for C₂₈H₂₇O₈Co₂ ([M+H]⁺): 609.0364, found: 609.0361.

4 (retention time: 14.3 min): red oil; IR (neat): 2014 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): . δ 7.19 (d, J = 8.8 Hz, 1H), 6.71 (d, J = 8.8 Hz, 1H), 5.94 (s, 1H), 4.26 (d, J = 15.1 Hz, 1H), 4.14 (d, J = 15.1 Hz, 1H), 3.81 (s, 3H), 3.06 (dd, J = 16.7 Hz, 5.8 Hz, 1H), 2.93-2.84 (m, 1H), 2.51 (dd, J = 18.5 Hz, 8.8 Hz, 1H), 2.39 (br s, 1H), 2.27 (br s, 1H), 2.20-2.05 (m, 4H), 1.66-1.40 (m, 6H), 0.90 (s, 3H);¹³C-NMR (100 MHz, CDCl₃): δ 220.9, 199.8, 155.0, 135.5, 132.5, 126.7, 124.8, 107.8, 95.9, 73.6, 54.7, 50.5, 47.9, 44.2, 37.7, 35.9, 31.6, 29.8, 27.0, 26.5, 26.1, 21.6, 13.8; HRMS (ESI): calcd for C₂₈H₂₆O₈Co₂Na ([M+Na]⁺): 631.0184, found: 631.0184.

5 (retention time: 11.7 min): red oil; IR (neat): 2017 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): . δ 7.18 (s, 1H), 6.09 (s, 1H), 5.92 (s, 1H), 4.19 (s, 2H), 4.17 (s, 2H), 3.81 (s, 3H), 3.02 (dd, *J* = 17.1 Hz, 5.4 Hz, 1H), 2.90-2.81 (m, 1H), 2.51 (dd, *J* = 18.4 Hz, 8.6 Hz, 1H), 2.36 (br s, 1H), 2.21-2.04 (m, 4H), 1.97 (d, *J* = 9.6 Hz, 1H), 1.65-1.43 (m, 6H), 0.88 (s, 3H); ¹³C-NMR (100 MHz, CDCl₃): δ 220.7, 199.7, 154.3, 136.4, 134.8, 131.9, 130.2, 126.5, 96.2, 95.2, 74.2, 61.4, 50.5, 47.9, 44.3, 37.4, 35.9, 34.7, 31.6, 31.2, 27.0, 26.4, 25.9, 21.6, 13.7; HRMS (ESI): calcd for C₃₇H₂₇O₁₄Co₄ ([M-H]⁻): 930.8723, found: 930.8743.

Functionalization of mestranol (6) using 2,6-di-tert-butylpyridine as a base



The procedure A was followed, employing 2,6-di-*tert*-butylpyridine instead of Cs_2CO_3 as a base, with a reaction time of 30 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 20) to provide 7 (36.7 mg, 0.0579 mmol, 58%) and recovered **6** (11.2 mg, 0.0361 mmol, 36%).

7: red oil; IR (neat): 2033 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.21 (d, *J* = 8.6 Hz, 1H), 6.71 (dd, *J* = 8.6 Hz, 2.6 Hz, 1H), 6.63 (d, *J* = 2.6 Hz, 1H), 5.99 (s, 1H), 4.86 (d, *J* = 13.0 Hz, 1H), 4.72 (d, *J* = 13.0 Hz, 1H), 3.78 (s, 3H), 2.85-2.84 (m, 2H), 2.63 (s, 1H), 2.32-2.24 (m, 3H), 2.12-2.02 (m, 2H), 1.99-1.77 (m, 4H), 1.51-1.35 (m, 4H), 0.93 (s, 3H); ¹⁰C-NMR (100 MHz, CDCl₃): δ 199.7, 157.4, 137.9, 132.6, 126.4, 113.8, 111.5, 93.3, 85.7, 84.8, 76.1, 70.8, 65.8, 55.2, 49.4, 47.8, 43.5, 39.2, 36.7, 33.9, 29.8, 27.3, 26.5, 22.9, 12.8; HRMS (FAB): calcd for C₃₀H₂₉O₈Co₂ ([M+H]⁺): 635.0526, found: 635.0537.

Functionalization of mestranol (6) using Cs₂CO₃ as a base



The procedure A was followed with a reaction time of 30 min to provide a mixture (35.4 mg) of **8** (0.0260 mmol, 26%), **9** (0.0237 mmol, 24%) and recovered **6** (0.0148 mmol, 15%), and a mixture (4.50 mg) of **7** (<1.58 μ mol, <2%), **S4** (<0.689 μ mol, <1%) and **S5** (<0.896 μ mol, <1%) containing unseparatable and unknown byproduct. The ratio was determined by ¹H-NMR. In this case, 1.2 equivalent of **1a** was added.

The analytical samples were obtained by extensive silica gel column chromatography separation (AcOEt : hexane = 1 : 8 to 1 : 4).

8: red oil; IR (neat): 2018 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.07 (s, 1H), 6.56 (s, 1H), 5.99 (s, 1H), 4.07 (s, 2H), 3.79 (s, 3H), 2.83 (br s, 2H), 2.60 (s, 1H), 2.37-2.30 (m, 2H), 2.20 (br s, 1H), 2.04-1.99 (m, 1H), 1.95-1.67 (m, 5H), 1.53-1.33 (m, 4H), 0.88 (s, 3H); ¹³C-NMR (100 MHz, CDCl₃): δ 199.9, 154.9, 136.6, 132.0, 127.7, 125.9, 110.5, 98.5, 87.5, 79.9, 74.0, 73.7, 54.7, 49.4, 47.1, 43.4, 39.4, 39.0, 34.0, 32.8, 29.7, 27.3, 26.3, 22.8, 12.6; HRMS (ESI): calcd for C₃₀H₂₇O₈Co₂ ([M-H]⁻): 633.0364, found: 633.0394.

9: red oil; IR (neat): 2018 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.20 (d, *J* = 8.7 Hz, 1H), 6.70 (d, *J* = 8.7 Hz, 1H), 5.93 (s, 1H), 4.24 (d, *J* = 15.0 Hz, 1H), 4.13 (d, *J* = 15.0 Hz, 1H), 3.80 (s, 3H), 3.01 (d, *J* = 16.8 Hz, 1H), 2.88-2.79 (m, 1H), 2.60 (br s, 1H), 2.35 (br s, 2H), 2.24 (br s, 1H), 2.06-1.67 (m, 6H), 1.53-1.29 (m, 4H), 0.87 (s, 3H); ¹⁶C-NMR (100 MHz, CDCl₃): δ 199.8, 154.9, 135.7, 132.9, 126.6, 124.8, 107.7, 96.0, 87.5, 79.9, 74.0, 73.7, 54.7, 49.5, 47.0, 43.8, 39.0, 38.7, 32.7, 29.8, 27.2, 27.1, 26.6, 22.8, 12.6; HRMS (ESI): calcd for C₃₀H₂₇O₈Co₂ ([M-H]⁻): 633.0364, found: 633.0388.

A 1 : 1 mixture of **S4** and **S5**: red oil; IR (neat): 2019 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.18 (d, J = 8.7 Hz, 0.5H), 7.07 (s, 0.5H), 6.70 (d, J = 8.7 Hz, 0.5H), 6.55 (s, 0.5H), 6.00 (s, 1.5H), 5.93 (s, 0.5H), 4.86 (d, J = 13.0 Hz, 1H), 4.72 (d, J = 13.0 Hz, 1H), 4.24 (d, J = 14.7 Hz, 0.5H), 4.13 (d, J = 14.7 Hz, 0.5H), 4.07 (s, 1H), 3.80 (s, 1.5H), 3.79 (s, 1.5H), 3.02-2.98 (m, 0.5H), 2.88-2.82 (m, 1.5H), 2.63 (s, 1H), 2.33-2.24 (m, 3H), 2.21-1.99 (m, 3H), 1.88-1.74 (m, 4H), 1.53-1.33 (m, 4H), 0.93 (s, 1.5H), 0.92 (s, 1.5H); "C-NMR (100 MHz, CDCl₃): δ 199.9, 154.87, 154.86, 136.6, 135.7, 133.0. 132.1, 127.7, 126.6, 125.8, 124.8, 110.5, 107.7, 98.5, 96.0, 93.3, 85.70, 85.67, 84.9, 84.8, 76.1, 73.7, 70.8, 65.8, 54.75, 54.71, 49.48, 49.42, 47.8, 47.7, 43.8, 43.4, 39.2, 38.5, 36.7, 34.0, 29.7, 27.3, 27.2, 26.7, 26.4, 22.9, 12.8; HRMS (FAB): calcd for C₃₆H₃₀O₁₁Co₄ ([M-3CO]⁺): 873.9116, found: 873.9118.

Functionalization of benzyl (3,4-dimethoxyphenethyl)(methyl)carbamate (10)



The procedure A was followed with a reaction time of 30 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 8 to 1 : 2) to provide **10a** (45.5 mg, 0.0697 mmol, 70%) and **10b** (3.09 mg, 4.73 μ mol, 5%).

10a (a mixture of two rotamers): red oil; IR (neat): 2018 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.35-7.30 (m, 5H), 6.72 (s, 0.5H), 6.67 (s, 1H), 6.52 (s, 0.5H), 6.07 (s, 0.5H), 5.95 (s, 0.5H), 5.13 (s, 1H), 5.10 (s, 1H), 4.13 (s, 1H), 3.97 (s, 1H), 3.86 (s, 3H), 3.82 (s, 1.5H), 3.74 (s, 1.5H), 3.45 (br s, 2H), 2.93-2.84 (m, 5H); "C-NMR (100 MHz, CDCl₃): δ 199.8, 156.3, 148.5, 147.9, 137.1, 136.9, 131.2, 131.0, 128.8, 128.7, 128.2, 128.0, 113.7, 113.1, 97.4, 97.2, 73.6, 67.5, 67.2, 56.2, 56.0, 51.2, 50.8, 37.1, 36.8, 35.3, 34.8, 31.4, 30.9; HRMS (EI): calcd for C₂₂H₂₅NO₄Co₂ ([M-6CO]⁺): 485.0448, found: 485.0462.

10b (a mixture of two rotamers): red oil; IR (neat): 2019 cm⁻¹; ¹H-NMR (600 MHz, CDCl₃): δ 7.38-7.32 (m, 5H), 6.89 (d, J = 8.2 Hz, 0.5H), 6.79-6.73 (m, 1.5H), 5.98 (s, 0.5H), 5.88 (s, 0.5H), 5.12 (s, 1H), 5.11 (s, 1H), 4.23 (s, 1H), 4.06 (s, 1H), 3.85 (s, 2H), 3.82 (s, 4H), 3.44 (t, J = 7.6 Hz, 2H), 2.93 (s, 3H), 2.90-2.84 (m, 2H); "C-NMR (150 MHz, CDCl₃): δ 199.7, 156.0, 151.4, 147.4, 137.0, 136.8, 132.8, 132.5, 129.7, 129.6, 128.5, 128.0, 127.9, 127.8, 125.0, 111.5, 111.4, 95.9, 95.6, 73.8, 67.2, 67.0, 60.3, 55.8, 51.2, 50.6, 35.0, 34.5, 31.4, 30.9, 30.6; HRMS (ESI) C₂₈H₂₅Co₂O₁₀NNa ([M+Na]⁺) calcd for 676.0035, found: 676.0017.

Functionalization of indometacin methyl ester (11)³



The procedure A was followed with a reaction time of 30 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 25) to provide **11a** (35.6 mg, 0.0511 mmol, 51%) and **11b** (10.2 mg, 0.0146 mmol, 15%).

11a: red oil; IR (neat): 2020 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.63 (d, *J* = 7.8 Hz, 2H), 7.45 (d, *J* = 7.8 Hz, 2H), 6.90 (d, *J* = 9.0 H, 1H), 6.64 (d, *J* = 9.0 Hz, 1H), 5.91 (s, 1H), 4.55 (s, 2H), 3.90 (s, 2H), 3.83 (s, 3H), 3.70 (s, 3H), 2.37 (s, 3H); ^aC-NMR (100 MHz, CDCl₃): . δ 199.9, 171.7, 168.3, 152.9, 139.5, 137.2, 133.9, 131.7, 131.3, 129.1, 128.2, 119.4, 113.3, 111.6, 106.9, 96.7, 73.2, 55.6, 52.2, 31.3, 29.5, 13.2; HRMS (ESI): calcd for C₂₉H₂₁NO-₁₀ClCo₂ ([M+H]⁺): 695.9513, found: 695.9503.

11b: red oil; IR (neat): 2019 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.66 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 6.91 (s, 1H), 6.90 (s, 1H), 5.89 (s, 1H), 4.03 (s, 2H), 3.88 (s, 3H), 3.68 (s, 3H), 3.67 (s, 2H), 2.33 (s, 3H); ^aC-NMR (100 MHz, CDCl₃): δ 199.7, 171.3, 168.4, 153.8, 139.3, 135.2, 131.1, 134.1, 130.3, 129.5, 129.1, 125.1, 116.0, 112.6, 99.1, 97.9, 73.7, 55.1, 52.1, 34.6, 30.3, 13.4; HRMS (ESI): calcd for C₂₉H₂₀NO₁₀ClCo₂Na ([M+Na]⁺): 717.9332, found: 717.9320.

Functionalization of naproxen methyl ester $(12)^4$



The procedure A was followed with a reaction time of 30 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 12) to provide **12a** (52.6 mg, 0.0925 mmol, 93%).

12a: red oil; IR (neat): 2019 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.90 (d, J = 8.9 Hz, 1H), 7.75 (d, J = 9.9 Hz, 1H), 7.68 (s, 1H), 7.48 (d, J = 8.9 Hz, 1H), 7.24 (d, J = 9.9 Hz, 1H), 5.91 (s, 1H), 4.61 (s, 2H), 3.96 (s, 3H), 3.87 (q, J = 7.1 Hz, 1H), 3.68 (s, 3H), 1.59 (d, J = 7.1 Hz, 3H); ¹³C-NMR (100 MHz, CDCl₃): δ 199.7, 175.1, 154.0, 135.3, 131.8, 129.1, 128.8, 126.8, 126.4, 123.7, 121.1, 112.7, 96.2, 73.5, 55.6, 52.0, 45.2, 29.0, 18.5; HRMS (EI): calcd for C₁₉H₁₈O₄Co₂ ([M-5CO]⁺): 427.9869, found: 427.9864.

Functionalization of compound 13⁵



The procedure A was followed with a reaction time of 30 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 2) to provide **13a** (49.2 mg, 0.0758 mmol, 76%).

13a: red oil; IR (neat): 2018 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 8.18 (s, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.35 (d, J = 8.7 Hz, 1H), 7.08 (s, 2H), 7.06 (s, 1H), 6.04 (s, 1H), 4.29 (s, 2H), 3.94 (s, 3H), 3.89 (s, 6H), 3.82 (s, 3H); ¹⁶C-NMR (100 MHz, CDCl₃): δ 199.6, 196.4, 152.8, 141.4, 139.2, 134.2, 129.1, 128.6, 126.9, 124.3, 122.7, 116.0, 108.9, 107.6, 97.8, 73.5, 60.9, 56.3, 32.9, 29.9; HRMS (ESI): calcd for C₂₈H₂₂NO₁₀Co₂ ([M+H]⁺): 649.9902, found: 649.9902.

Functionalization of rotenone (14)



The procedure A was followed with a reaction time of 30 min. The crude product was

purified by HPLC (AcOEt : hexane = 3 : 7, 9 mL/min) to provide **14a** (18.9 mg, 0.0261 mmol, 26%) and **14b** (2.11 mg, 2.02 μmol, 2%).

14a (retention time: 10.8 min): red oil; IR (neat): 2017 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.83 (d, J = 8.4 Hz, 1H), 6.78 (s, 1H), 6.51 (d, J = 8.4 Hz, 1H), 6.00 (s, 1H), 5.28 (dd, J = 9.9 Hz, 8.0 Hz, 1H), 5.09 (s, 1H), 4.95-4.93 (m, 2H), 4.66 (dd, J = 11.9 Hz, 2.9 Hz, 1H), 4.17 (d, J = 11.9 Hz, 1H), 4.14 (s, 2H), 3.85 (d, J = 3.9 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 3.32 (dd, J = 15.7 Hz, 9.9 Hz, 1H), 3.01 (dd, J = 15.7 Hz, 8.0 Hz, 1H), 1.78 (s, 3H); "C-NMR (100 MHz, CDCl₃): δ 199.9, 188.8, 167.3, 158.0, 147.7, 147.2, 145.1, 143.0, 130.0, 122.3, 113.4, 112.8, 112.6, 110.8, 109.0, 104.8, 96.6, 87.8, 73.6, 72.1, 65.9, 60.5, 56.4, 45.0, 31.3, 27.6, 17.1; HRMS (ESI): calcd for C₃₂H₂₅O₁₂Co₂ ([M+H]⁺): 719.0005, found: 718.9995.

14b (retention time: 8.8 min): red oil; IR (neat): 2018 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.73 (s, 1H), 6.73 (s, 1H), 6.03 (s, 1H), 5.99 (s, 1H), 5.29 (t, J = 9.2 Hz, 1H), 5.11 (s, 1H), 4.98 (s, 1H), 4.91-4.89 (m, 1H), 4.64 (dd, J = 11.8 Hz, 3.1 Hz, 1H), 4.17 (d, J = 12.1 Hz, 1H), 4.14 (s, 2H), 4.07 (d, J = 15.5 Hz, 1H), 3.98 (d, J = 15.5 Hz, 1H), 3.83 (s, 4H), 3.72 (s, 3H), 3.32 (dd, J = 15.9 Hz, 9.7 Hz, 1H), 3.04 (dd, J = 15.8 Hz, 8.4 Hz, 1H), 1.81 (s, 3H); "C-NMR (100 MHz, CDCl₃): δ 199.8, 188.8, 165.3, 157.1, 147.7, 147.1, 145.1, 142.8, 129.8, 122.3, 117.5, 113.3, 113.03, 112.98, 110.8, 109.0, 96.7, 96.2, 88.1, 73.67, 73.63, 72.2, 65.9, 60.6, 56.3, 45.1, 33.3, 31.6, 27.6, 17.3; HRMS (ESI): calcd for C₄₁H₂₇O₁₈Co₄ ([M+H]⁺): 1042.8520, found: 1042.8508.

Functionalization of xanthotoxin (15)



The procedure B was followed with a reaction time of 2 h. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 4) to provide 15a (15.1 mg, 0.0280 mmol, 28%) along with recovered 15 (14.5 mg, 0.0669 mmol, 67%)

15a: red oil; IR (neat): 2021 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 8.03 (d, J = 9.8 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 6.91 (d, J = 2.0 Hz, 1H), 6.47 (d, J = 9.8 Hz, 1H), 5.95 (s, 1H), 4.50 (s, 2H), 4.24 (s, 3H); ¹⁰C-NMR (100 MHz, CDCl₃): δ 199.1, 160.0, 147.3, 146.7, 143.9, 140.3, 132.3, 125.9, 123.5, 114.7, 114.1, 105.3, 94.2, 73.0, 61.5, 33.1; HRMS (ESI): calcd for C₂₁H₁₁O₁₀Co₂ ([M+H]⁺): 540.9011, found: 540.8994.

Functionalization of colchicine (16)



On 0.05 mmol scale, the procedure B was followed, employing 20 equiv. of Cs_2CO_3 instead of 10 equiv. with a reaction time of 1 h. The crude product was purified by silica gel column chromatography (MeOH : CHCl₃ = 1 : 40) to provide **16a** (2.83 mg, 3.91 µmol, 8%) and recovered **16** (15.7 mg, 0.0392 mmol, 79%).

16a: red oil; IR (neat): 2022 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.56 (br s, 1H), 7.54 (s, 1H), 7.21 (d, J = 10.7, 1H), 6.85 (d, J = 10.7 Hz, 1H), 5.93 (s, 1H), 4.66-4.60 (m, 1H), 4.32 (d, J = 13.4 Hz, 1H), 4.00 (s, 6H), 3.92 (d, J = 13.4 Hz, 1H), 3.91 (s, 3H), 3.61 (s, 3H), 2.90-2.88 (m, 1H), 2.27-2.25 (m, 2H), 2.00 (s, 3H), 1.90-1.87 (m, 1H); "C-NMR (100 MHz, CDCl₃): . δ 199.7, 179.6, 170.1, 164.2, 152.1, 151.6, 150.5, 145.5, 136.7, 135.6, 132.1, 130.2, 129.4, 126.6, 112.7, 96.2, 96.1, 73.4, 61.4, 60.9, 60.7, 56.4, 52.5, 35.9, 30.3, 25.5, 22.9; HRMS (ESI): calcd for C₃₁H₂₇NO₁₂Co₂Na ([M+Na]⁺): 746.0089, found: 746.0067.

Funtionalization of estradiol (17)



The procedure A was followed with a reaction time of 30 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 8) to provide 17a (15.3 mg, 0.0166 mmol, 17%), 17b (8.88 mg, 0.0149 mmol, 15%), 17c (13.6 mg, 0.0227 mmol, 23%) and recovered 17 (8.90 mg, 0.0327 mmol, 33%). In this case, starting material 17 was dissolved in 5 ml of $CH_2Cl_2(0.02 \text{ M})$ and added.

17a: red oil; IR (neat): 2017 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.02 (s, 1H), 6.04 (s, 1H), 5.98 (s, 1H), 4.80 (s, 1H), 4.18 (s, 2H), 4.13 (d, *J* = 16.1 Hz, 1H), 4.06 (d, *J* = 16.1 Hz, 1H), 3.73 (br d, *J* = 5.9 Hz, 1H), 2.94 (br d, *J* = 16.1 Hz, 1H), 2.81 (dd, *J* = 15.9 Hz, 10.5 Hz, 1H), 2.28 (br d, *J* = 11.2 Hz, 1H), 2.15 (br s, 2H), 1.95 (br d, *J* = 10.7 Hz, 2H), 1.70 (br s, 1H), 1.49-1.19 (m, 10H), 0.76 (s, 3H); ¹⁰C-NMR (100 MHz, CDCl₃): δ 199.5, 149.2, 134.7, 133.6, 126.3, 125.2, 123.8, 95.6, 94.1, 81.9, 73.6, 72.9, 50.0, 44.1, 43.2, 38.1, 36.7, 35.3, 30.6, 27.2, 26.4, 23.1, 11.0; HRMS (ESI): calcd for C₃₆H₂₇O₁₄Co₄ ([M-H]⁻): 918.8723, found: 918.8710.

17b: red oil; IR (neat): 2017 cm⁻¹; ¹H-NMR (400 MHz, CD₃COCD₃): δ 8.15 (s, 1H), 7.11 (s, 1H), 6.57 (s, 1H), 6.40 (s, 1H), 4.17 (d, *J* = 15.0 Hz, 1H), 4.10 (d, *J* = 15.0 Hz, 1H), 3.65 (br s, 1H), 3.58 (br s, 1H), 2.30 (br s, 1H), 2.12-1.95 (m, 3H), 1.83 (br s, 1H), 1.64 (br s, 1H), 1.46-1.19 (m, 10H), 0.76 (s, 3H); HRMS (ESI): calcd for C₂₇H₂₅O₈Co₂ ([M-H]⁻): 595.0208, found: 595.0211.

17c: red oil; IR (neat): 2017 cm⁻¹; ¹H-NMR (400 MHz, CD₃COCD₃): δ 8.25 (br s, 1H), 7.04 (d, *J* = 8.2 Hz, 1H), 6.69 (d, *J* = 8.2 Hz, 1H), 6.37 (s, 1H), 4.28 (d, *J* = 14.7 Hz, 1H), 4.22 (d, *J* = 14.7 Hz, 1H), 3.66 (br s, 1H), 3.57 (br s, 1H), 3.03 (br s. 1H), 2.25 (brs, 1H), 2.13 (br s, 1H), 1.95 (br s, 4H), 1.48-1.19 (m, 8H), 0.75 (s, 3H); HRMS (ESI): calcd for C₂₇H₂₅O₈Co₂ ([M-H]⁻): 595.0208, found: 595.0224.

Functionalization of podophyllotoxin (18)



The procedure A was followed with a reaction time of 10 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 8) to provide **18a** (20.4 mg, 0.0276 mmol, 28%).

18a: red oil; IR (neat): 2029 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.07 (s, 1H), 6.52 (s, 1H), 6.37 (s, 2H), 6.08 (s, 1H), 5.98 (d, *J* = 1.0 Hz, 1H), 5.96 (d, *J* = 1.0 Hz, 1H), 4.82 (d, *J* = 10.7 Hz, 1H), 4.77 (d, *J* = 12.1 Hz, 1H), 4.69 (d, *J* = 12.1 Hz, 1H), 4.62-4.58 (m, 2H), 4.16 (t, *J* = 9.7 Hz, 1H), 3.81 (s, 3H), 3.72 (s, 6H), 3.04-2.95 (m, 1H), 2.87 (dd, *J* = 14.2 Hz, 4.6 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃): δ 199.3, 173.9, 152.6, 147.9, 147.7, 137.0, 135.3, 131.8, 130.3, 109.7, 107.9, 106.8, 101.5, 90.3, 78.0, 71.4, 71.2, 68.7, 60.7, 55.9, 45.5, 43.9, 37.8; HRMS (ESI): calcd for C₃₁H₂₅O₁₄Co₂ ([M+H]⁺): 738.9903, found: 738.9888.

Functionalization of eugenol (19)



On 0.200 mmol scale, the procedure A was followed, employing K_2CO_3 instead of Cs_2CO_3 as a base, with a reaction time of 2 h. The crude product was purified by silica gel column

chromatography (AcOEt : hexane = 1 : 20 to 1 : 8) to provide a mixture of **19a** (18.4 mg, 0.0369 mmol, 15%) and **19b** (7.23 mg, 14.5 μ mol, 7%) and a single product of **19a** (15.1 mg, 0.0303 mmol, 18%). The mixture of **19b** and **19c** was separated by HPLC (AcOEt : hexane = 1 : 19, 9.4 mL/min).

19a: red oil; IR (neat): 2020 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 6.81 (s, 1H), 6.65 (s, 1H), 6.04 (s, 1H), 5.97 (ddt, J = 17.0 Hz, 10.3 Hz, 6.4 Hz, 1H), 5.46 (s, 1H), 5.11 (dt, J = 10.3 Hz, 1.4 Hz, 1H), 5.04 (dt, J = 17.0 Hz, 1.4 Hz, 1H), 4.04 (s, 2H), 3.85 (s, 3H), 3.43 (dd, J = 6.4 Hz, 1.4 Hz, 2H); ¹³C-NMR (100 MHz, CDCl₃): δ 199.6, 145.7, 144.1, 137.2, 131.6, 128.8, 116.1, 115.9, 112.2, 97.1, 73.5, 56.0, 36.82, 36.78; HRMS (ESI): calcd for C₁₉H₁₄O₈Co₂Na ([M+Na]⁺): 510.9245, found: 510.9238.

19b (retention time: 19.0 min): red oil; IR (neat): 2020 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): . δ 6.61 (s, 1H), 6.60 (s, 1H), 6.03 (s, 1H), 5.92 (ddt, J = 16.8 Hz, 10.0 Hz, 6.5Hz, 1H), 5.60 (s, 1H), 5.09-5.04 (m 2H), 4.10 (s, 2H), 3.86 (s, 3H), 3.30 (d, J = 6.5 Hz, 2H); ¹⁰C-NMR (100 MHz, CDCl₃): δ 199.7, 146.4, 141.9, 137.7, 131.3, 125.9, 122.7, 115.5, 109.9, 97.3, 73.7, 56.1, 39.9, 33.6; HRMS (EI): calcd for C₁₈H₁₄O₇Co₂ ([M-CO]⁺): 459.9404, found: 459.9400.

19c (retention time: 20.7 min): red oil; IR (neat): 2023 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): . δ 6.88 (d, J = 9.0 Hz, 1H), 6.73 (s, 1H), 6.72 (d, J = 9.0 Hz, 1H), 6.03 (s, 1H), 6.01-5.91 (m, 1H), 5.25 (s, 2H), 5.10-5.06 (m, 2H), 3.81 (s, 3H), 3.34 (d, J = 6.8 Hz, 2H); ¹⁶C-NMR (100 MHz, CDCl₃): δ 199.2, 150.2, 145.9, 137.6, 134.1, 120.3, 115.7, 115.1, 112.9, 89.6, 72.4, 69.7, 55.7, 39.9; HRMS (EI): calcd for C₁₂H₁₄O₂Co₂ ([M-6CO]⁺): 319.9658, found: 319.9637.

6. Decomplexation of dicobalt hexacarbonyl complexes

Standard procedure: To a solution of cobalt complex in MeCN (0.01 M) was added TEMPO⁺BF₄⁻ (0.5 equiv. \times 8 or 9) every 5 min at - 40 °C. After completion of the reaction, the reaction was quenched with sat. NaHCO₃ (2 mL) and extracted with AcOEt (4 mL \times 3). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography.

Decomplexation of compound 19a



On 11.7 mg (0.0234 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻

(total 25.23 mg, 0.104 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 4) to provide **20** (4.05 mg, 0.0200 mmol, 86%).

20: colorless oil; IR (neat): 3294, 205w cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.06 (s, 1H), 6.66 (s, 1H), 5.93 (ddt, J = 16.9 Hz, 10.2 Hz, 6.3 Hz, 1H), 5.46 (s, 1H), 5.06 (dd, J = 10.2 Hz, 1.4 Hz, 1H), 4.99 (dd, J = 16.9 Hz, 1.4 Hz, 1H), 3.87 (s, 3H), 3.46 (d, J = 2.4 Hz, 2H), 3.35 (d, J = 6.3 Hz, 2H), 2.15 (t, J = 2.4 Hz, 1H); ¹⁵C-NMR (100 MHz, CDCl₃): δ 145.4, 144.1, 136.6, 128.8, 127.2, 115.8, 115.1, 112.3, 82.1, 70.4, 56.0, 36.8, 21.7; HRMS (EI): calcd for C₁₃H₁₄O₂ (M⁺): 202.0994, found: 202.0986.

Decomplexation of compound 10a



On 44.6 mg (0.0683 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 74.5 mg, 0.306 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 1) to provide **21** (20.4 mg, 0.0555 mmol, 81%).

21: colorless oil; IR (neat): 3286 cm⁻¹; ¹H-NMR (400 MHz, CD₃SOCD₃): δ 7.36-7.30 (m, 5H), 6.97 (s, 1H), 6.72 (s, 1H), 5.06 (s, 2H), 3.74 (s, 1H), 3.70 (s, 3H), 3.49 (d, *J* = 2.5 Hz, 2H), 3.42 (t, *J* = 7.5 Hz, 2H), 2.86 (s, 3H), 2.78 (t, *J* = 7.5 Hz, 2H), 2.78 (t, *J* = 2.5 Hz, 1H); ¹⁰C-NMR (100 MHz, CD₃SOCD₃): δ 154.9, 147.7, 147.3, 136.6, 128.8, 127.8, 127.1, 126.9, 126.6, 114.5, 113.8, 82.2, 71.7, 65.7, 55.7, 48.8, 40.1, 33.8, 29.6, 20.7; HRMS (EI): calcd for C₂₂H₂₅NO₄ (M⁺): 367.1784, found: 367.1790.

Decomplexation of compound 11b



On 10.4 mg (0.0149 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 15.9 mg, 0.0656 mmol) and a reaction time of 40 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 12) to provide **22** (4.42 mg, 0.0108 mmol, 72%).

22: colorless oil; IR (neat): 3301 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.67 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 7.01 (s, 1H), 6.89 (s, 1H), 3.87 (s, 3H), 3.70 (s, 3H), 3.68 (s, 2H), 3.49 (d, J = 2.6 Hz, 2H), 2.46 (s, 3H), 1.97 (t, J = 2.6 Hz, 1H); ^aC-NMR (100 MHz, CDCl₃): δ 171.4, 168.4, 153.4, 139.0, 135.5, 134.0, 131.1, 130.2, 129.14, 129.08, 120.7. 114.7, 112.5, 98.7, 81.5, 70.6, 55.7, 52.1, 30.2, 19.7, 13.3; HRMS (ESI): calcd for C₂₃H₂₁NO₄Cl ([M+H]⁺): 410.1154, found: 410.1148.

Decomplexation of compound 12a



On 40.1 mg (0.0706 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 62.2 mg, 0.285 mmol) and a reaction time of 40 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 20) to provide **23** (18.2 mg, 0.0643 mmol, 91%).

23: colorless oil; IR (neat): 3290 cm⁻¹; ¹H-NMR (600 MHz, CDCl₃): δ 8.02 (d, *J* = 8.9 Hz, 1H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.69 (s, 1H), 7.50 (d, *J* = 8.9 Hz, 1H), 7.26 (d, *J* = 7.9 Hz, 1H), 3.97 (d, *J* = 2.3 Hz, 1H), 3.97 (s, 3H), 3.87 (q, *J* = 7.0 Hz, 1H), 3.67 (s, 3H), 1.97 (t, *J* = 2.3 Hz, 1H), 1.58 (d, *J* = 7.0 Hz, 3H); "C-NMR (150 MHz, CDCl₃): δ 175.0, 154.0, 135.6, 131.8, 129.3, 128.8, 126.7, 123.8, 117.5, 113.9, 82.8, 67.9, 56.8, 52.0, 45.2, 18.5, 14.4; HRMS (ESI): calcd for C₁₈H₁₉O₃ ([M+H]⁺): 283.1329, found: 283.1324.

Decomplexation of compound 13a



On 49.2 mg (0.0758 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 84.1 mg, 0.346 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 2) to provide **24** (25.6 mg, 0.0704 mmol, 93%).

24: white amorphous; IR (neat): 3285 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 8.16 (d, J = 1.4 Hz, 1H), 7.80 (dd, J = 8.7 Hz, 1.4 Hz, 1H), 7.37 (d, J = 8.7 Hz, 1H), 7.13 (s, 1H), 7.10 (s, 2H), 3.95 (s, 3H), 3.88 (s, 6H), 3.82 (s, 3H), 3.70 (d, J = 2.6 Hz, 2H), 2.13 (t, 2.6 Hz, 1H); ¹⁰C-NMR (100 MHz, CDCl₃): δ 196.2, 152.8, 141.4, 139.4, 134.1, 129.0, 128.4, 126.3, 124.2, 122.9, 111.5, 109.1, 107.7, 82.0, 69.3, 61.0, 56.3, 32.9, 15.1; HRMS (EI): calcd for

 $C_{22}H_{21}NO_4$ (M⁺): 363.1471, found 363.1485.

Decomplexation of compound 17a



On 19.0 mg (0.0318 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 31.9 mg, 0.131 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 4 to 1 : 2) to provide **25** (7.13 mg, 0.0230 mmol, 72%).

25: colorless oil; IR (neat): 3305, 2115 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.12 (d, *J* = 8.3 Hz, 1H), 6.67 (d, *J* = 8.3 Hz, 1H), 5.23 (br s, 1H), 3.74 (t, *J* = 8.3 Hz, 1H), 3.55 (d, *J* = 2.4 Hz, 1H), 2.99-2.93 (m, 1H), 2.85-2.81 (m, 1H), 2.33-2.27 (m, 1H), 2.23-2.10 (m, 2H), 2.02 (t, *J* = 2.4 Hz, 1H), 2.00-1.92 (m, 2H), 1.75-1.68 (m, 1H), 1.54-1.14 (m, 7H), 0.77 (s, 3H); "C-NMR (100 MHz, CDCl₃): δ 151.3, 136.2, 133.5, 125.1, 120.8, 113.3, 81.9, 81.8, 68.4, 50.0, 44.2, 43.2, 38.0, 36.7, 30.6, 27.3, 26.9, 26.6, 23.1, 15.2, 11.0; HRMS (ESI): calcd for C₂₁H₂₅O₂ ([M-H]⁻): 309.1849, found: 309.1863.

Decomplexation of compound 9



On 0.208 mmol scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 22. 7 mg, 0.093 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 8 to 1 : 4) to provide **26** (6.83 mg, 0.0196 mmol, 94%).

26: colorless oil; IR (neat): 3301 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.22 (d, *J* = 8.5 Hz, 1H), 6.76 (d, *J* = 8.5 Hz, 1H), 3.84 (s, 3H), 3.55 (s, 2H), 3.02 (dd, *J* = 17.4 Hz, 4.8 Hz, 1H), 2.89-2.80 (m, 1H), 2.61 (s, 1H), 2.39-2.23 (m, 3H), 2.04-1.66 (m, 8H), 1.56-1.33 (m, 5H), 0.88 (s, 3H); ¹³C-NMR (100 MHz, CDCl₃): δ 154.8, 136.5, 133.2, 124.9, 122.9, 108.5, 87.6, 82.5, 79.9, 74.0, 67.0, 55.9, 49.5, 47.0, 43.8, 39.0, 38.6, 32.8, 27.3, 26.7, 26.6, 22.8, 14.9, 12.6; HRMS (ESI): calcd for C₂₄H₂₉O₂ ([M+H]⁺): 349.2162, found: 349.2160.

Decomplexation of compound 7



On 32.5 mg (0.0511 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 59.0 mg, 0.243 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (CH₂Cl₂) to provide **27** (15.1 mg, 0.0434 mmol, 85%).

27: colorless oil; IR (neat): 3288 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.20 (d, *J* = 8.4 Hz, 1H), 6.71 (dd, *J* = 8.4 Hz, 2.2 Hz, 1H), 6.63 (s, 1H), 4.34 (s, 2H), 3.77 (s, 3H), 2.87-2.84 (m, 2H), 2.67 (s, 1H), 2.43 (s, 1H), 2.35-2.25 (m, 3H), 2.22-2.09 (m, 1H), 2.02-1.94 (m, 1H), 1.88-1.71 (m, 4H), 1.54-1.30 (m, 4H), 0.92 (s, 3H); ¹⁵C-NMR (100 MHz, CDCl₃): δ 157.4, 137.9, 132.5, 126.3, 113.8, 111.5, 86.1, 83.9, 80.8, 76.8, 73.5, 55.2, 53.9, 49.4, 47.7, 43.4, 39.2, 37.1, 33.9, 29.8, 27.2, 26.5, 22.8, 12.8; HRMS (ESI): calcd for C₂₄H₂₉O₂ ([M+H]⁺): 349.2162, found: 349.2159.

Decomplexation of compound 19b



On 13.1 mg (0.0263 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 25.3 mg, 0.104 mmol) and a reaction time of 40 min. The crude product was purified by silica gel column chromatography (CH₂Cl₂ : hexane = 1 : 4) to provide **28** (3.01 mg, 0.0149 mmol, 58%) and recovered **19b** (1.27 mg, 2.55 μ mol, 10%).

28: colorless oil; IR (neat): 3307, 2120 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 6.89 (d, J = 3.0 Hz, 1H)), 6.61 (d, J = 3.0 Hz, 1H), 5.96 (ddt, J = 16.8 Hz, 10.0 Hz, 6.5 Hz, 1H), 5.62 (s, 1H), 5.11-5.05 (m, 2H), 3.87 (s, 3H), 3.58 (d, J = 2.8 Hz, 2H), 3.33 (d, J = 6.5 Hz, 2H), 2.15 (t, J = 2.8 Hz, 1H); ^aC-NMR (100 MHz, CDCl₃): δ 146.1, 141.3, 137.8, 131.4, 121.7, 121.1, 115.6, 109.7, 81.9, 69.9, 56.1, 40.0, 18.8; HRMS (ESI): calcd for C₁₃H₁₅O₂ ([M+H]⁺): 203.1067, found: 203.1068.

Decomplexation of compound 17b



On 15.43 mg (0.0260 mmol) scale, the standard procedure was followed with TEMPO⁺BF₄⁻ (total 30.5 mg, 0.125 mmol) and a reaction time of 45 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 8 to 1 : 4) to provide **29** (2.68 mg, 8.63 μ mol, 33%) and recovered **17b** (4.03 mg, 6.76 μ mol, 26%).

29: colorless oil; IR (neat): 3306 cm⁻¹; ¹H-NMR (400 MHz, CDCl₃): δ 7.22 (s, 1H), 6.54 (s, 1H), 5.12 (br s, 1H), 3.73 (t, *J* = 8.5 Hz, 1H), 3.54 (d, *J* = 2.8 Hz, 2H), 2.82-2.78 (m, 2H), 2.35-2.31 (m, 1H), 2.22 (t, *J* = 2.8 Hz, 1H), 2.17-2.07 (m, 2H), 1.98-1.93 (m, 1H), 1.88-1.84 (m, 1H), 1.73-1.66 (m, 1H), 1.52-1.15 (m, 8H), 0.78 (s, 3H); ^(a)C-NMR (100 MHz, CDCl₃): . δ 151.3, 137.0, 133.0, 126.5, 119.5, 115.9, 81.9, 81.6, 70.9, 50.0, 44.0, 43.3, 38.8, 36.7, 30.6, 29.7, 29.2, 27.2, 26.4, 23.1, 19.8, 11.0; HRMS (ESI): calcd for C₂₁H₂₅O₂ ([M-H]⁻): 309.1849, found: 309.1860.

Decomplexation of compound 10b



On 8.73 mg (0.0133 mmol) scale, the standard procedure was followed with TEMPO (13.0 mg, 0.0535 mmol) and a reaction time of 40 min. The crude product was purified by silica gel column chromatography (AcOEt : hexane = 1 : 4 to 1 : 1) to provide **S6** (3.86 mg, 0.0105 mmol, 79%).

S6: colorless oil; IR (neat): 3289 cm⁻¹; ¹H-NMR (400 MHz, CD₃SOCD₃): δ 7.36-7.30 (m, 5H), 7.36 (d, *J* = 8.6 Hz, 1H), 7.31 (d, *J* = 8.6 Hz, 1H), 5.07 (s, 2H), 3.79 (s, 3H), 3.77 (s, 3H), 3.51 (d, *J* = 2.7 Hz, 2H), 3.44 (t, *J* = 7.8 Hz, 2H), 2.86 (s, 3H), 2.84 (t, *J* = 7.8 Hz, 2H), 2.60 (t, *J* = 2.7 Hz, 1H); ¹³C-NMR (100 MHz, CD₃SOCD₃): δ 154.9. 150.6, 146.6, 136.7, 129.6, 128.7, 127.8, 127.1, 126.9, 124.4, 111.8, 82.6, 69.7, 65.7, 59.7, 55.5, 49.1, 33.8, 29.8, 14.6; HRMS (ESI) C₂₂H₂₆O₄N ([M+H]⁺) calcd for 368.1856, found 368.1852.

7. References

- M. Gruselle, V. Philomin, F. Chaminant, G. Jaouen and K. M. Nicholas, J. Organomet. Chem., 1990, 399, 317-326.
- 2. L. El Kaim, L. Grimaud, A. Lee, Y. Perroux and C. Tirla, Org. Lett., 2004, 6, 381-383.
- 3. G. Fronza, A. Mele, E. Redenti and P. Ventura, J. Org. Chem., 1996, 61, 909-914.
- 4. W. L. Noorduin, B. Kaptein, H. Meekes, W. J. van Enckevort, R. M. Kellogg and E. Vlieg, *Angew. Chem. Int. Ed.*, **2009**, *48*, 4581-4583.
- R. Alvarez, P. Puebla, J. F. Diaz, A. C. Bento, R. Garcia-Navas, J. de la Iglesia-Vicente, F. Mollinedo, J. M. Andreu, M. Medarde and R. Pelaez, *J. Med. Chem.*, 2013, 56, 2813-2827.

8. ¹H-NMR Comparison of aromatic bioactive small molecules and their dicobalt hexacarbonyl complexes

Arrows indicate protons substituted by the propargyl dicobalt hexacarbonyl group.

 $C: \label{eq:c:store} E = C: \ensuremath{\texttt{YUsers}} \ensuremath{\texttt{gosei}} \ensuremath{\texttt{Formula}} \ensuremath{\texttt{Sets}} \ensuremath{\texttt{$



$C: {\tt YUsers {\tt Ygosei {\tt YDesktop {\tt Yalkyne functionalization {\tt Ymestranol {\tt Ymestranol {\tt 2-1} H_set.als}}}$



 $C: \ensuremath{{\tt YUsers}{\tt Ygosei}{\tt YDesktop}{\tt Yalkyne\ functionalization}{\tt Yindometacin}{\tt Yindometacin}{\tt Interval}{\tt Halkyne\ functionalization}{\tt Yindometacin}{\tt Yi$



 $C: \ensuremath{{\tt YUsers}{\tt Ygosei}{\tt YDesktop}{\tt Yalkyne\ functionalization}{\tt Yindometacin}{\tt Yindometacin$



 $C: \label{eq:c:store} E = C: \ensuremath{\texttt{YUsers}} \ensuremath{\texttt{YDesktop}} \ensuremath{\texttt{Yalkyne}}\xspace \ensuremath{\texttt{Int}}\xspace \ensuremath{\texttt{Yalkyne}}\xspace \ensuremath{\texttt{Yalk$



24

 $C: {\tt {\tt YUsers {\tt Ygosei {\tt YDesktop {\tt Yalkyne functionalization {\tt Yxanthotoxin {\tt Yxanthotoxin {\tt -1} H_set.als}}}$



 $C: {\tt ¥Users} {\tt ¥gosei} {\tt ¥Desktop} {\tt ¥alkyne functionalization} {\tt ¥antiprofileactivity} {\tt ¥antiprofileactivity} {\tt H_set.als}$



 $C: \label{eq:c:store} E = C: \ensuremath{\texttt{YUsers}}\xspace \ensuremath{\texttt{gosei}}\xspace \ensuremath{\texttt{POS}}\xspace \ensuremath{\texttt{hore}}\xspace \ensuremath{\texttt{stars}}\xspace \ensuremath{\texttt{st$





 $C: \ensuremath{{\tt YUsers}{\tt Ygosei}{\tt YDesktop}{\tt Yalkyne functionalization}{\tt Ycolchicine}{\tt Ycolchicine-1H_set.als}$



 $C: {\tt FUsers {\tt Fgosei {\tt FDesktop {\tt Falkyne functionalization {\tt Feugenol {\tt Feugenol {\tt Full {} Full {\tt Full {} Full {\tt Full {\tt Full {\tt Full {\tt Full {} Full {\tt Full {} Full {\tt Full {} Full} Full {} Ful$



 $C: {\tt YUsers {\tt Ygosei {\tt YDesktop {\tt Yalkyne functionalization {\tt Yeugenol {\tt Yeugenol {\tt H-set.als}}}}}$



9. NMR Spectra



DeW	$ \begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $				77.338			DFILE mestrone1-13C_set.als COMNT auto DATIM Mon Feb 08 07:53:08 2016 OBNUC 13C EXMOD BCM OBFRQ 99.45 MHz OBSET 94.00 KHz OBFIN 10309.00 Hz POINT 32768 FREQU 26845.64 Hz SCANS 9718 ACQTM 1.2206 sec PD 1.7790 sec PW1 6.50 usec IRNUC 1H CTEMP 22.0 c SLVNT CDCL3 EXREF 0.00 ppm BF 0.52 Hz RGAIN 22
NO WARRANG OF THE PASSAGE		i peladan yaharka kohkapanyak kelanganjai yakang	n minima secondar se		internet and the second s			
220.0	210.0 200.0 190.0 180.0 170.	0 160.0 150.0	140.0 130.0 120.	0 110.0 100.0	90.0 80.0 70.0	60.0 50.0 40.0 30.0 20.0	PPM 10.0 0.0	

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestrone¥mestrone1-13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestrone¥mestrone2-1H_set.als




36

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestrone¥mestrone2-13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestrone¥mestrone3-1H_set.als





auto <u>C</u>:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestrone¥mestrone3–13C_set.als



DFILE mestranol3-13C_set.als COMNT auto 199.686 126.356 113.780111.476157.441 137.927 132.59485.683 84.835 77.321 77.206 77.000 76.679 76.070 76.070 76.070 76.824 49.429 47.791 43.503 39.174 36.722 33.948 33.948 29.817 27.265 26.500 226.500 22.862 93.296 55.182 12.805 DATIM Thu Mar 24 15:21:18 2016 OBNUC 13C 85. EXMOD BCM OBFRQ 99.45 MHz 94.00 KHz OBSET OBFIN 10309.00 Hz POINT 32768FREQU 26845.64 Hz $(OC)_6 Co_2 - \frac{11}{11}$ SCANS 745 ACQTM 1.2206 sec 1.7790 sec PD 6.50 usec PW1 OIRNUC 1H !..= CTEMP 23.7 с CDCL3 SLVNT н EXREF 77.00 ppm BF 1.02 Hz RGAIN 23 Ĥ Ĥ MeO 7 PPM המקום המתקדות המקום המקום המקום המקום המקום המקום המקום המקום המתקדות המקום המתקדות המקום המקום המקום ה 210.0 200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol¥mestranol3–13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol¥mestranol1-1H.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol¥mestranol1-13C_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol4mestranol2-1H_set.als





44

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol¥mestranol2–13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorylamine¥N-Cbz,MeHVA-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorylamine¥N-Cbz,MeHVA-13C_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorilamine¥N-Cbz,MeHVA1-1H_set.als



10a

Structure determined after decomplexation.





auto	
$C: \ensuremath{{\tt YUsers}{\tt Yusers}{\tt Fgosei}{\tt YDesktop}{\tt Yalkyne functionalization}{\tt YN-CBZ-methyl homoverate} and \ensuremath{{\tt SH}{\tt Phi}} and \ensuremath{{\tt SH}{\tt Phi}} and \ensuremath{{\tt CH}{\tt Phi}} and \ensuremath{{\tt SH}{\tt Phi}} and \en$	rilamine¥N-Cbz,MeHVA1-13C_set.als

MeO MeO		10a		Cbz	: O) ₆						read Otherstein	Takanak Videor	10 2005 7 4 40			natalise					4.0% 64-0.0 × 0.4			DFILE COMNT DATIM OBNUC EXMOD OBFET OBFIN POINT FREQU SCANS ACQTM PD PW1 IRNUC CTEMP SLVNT EXREF BF RGAIN	N-Cbz,Me auto Thu Apr 1- 13C BCM 99.45 94.00 10309.0 32765 26845.6 10491 1.2206 1.7790 6.50 1H 25.5 CD2CL 77.20 1.02 23	HVA1-13C 4 08:59:28 2 KHz 00 Hz 3 44 Hz 5 sec 0 sec usec c 9 ppm Hz	_set.als 2016
310 0 4 	200 0 11111111 1011111111	100 0	190.0		160 0	150 0	140.0	ייזיייי אייזיייי רדרדדדדדד 1900	190 0 1111111111111111111111111111111111	110 (100 (1111111111111111111111111111111111	, 00 	را بېلىكىنى بار بېلىكىنى بەر بەر بىلى	0 2	ייי ו יזי ייזין דו דו דו דו 70.0	- 60 0	ייייניי זיינין דדרךדדדד 50.0	10 0 1111111111111111111111111111111111	י יי ן י זי רדדדד מי	10 0 11111111 10 001000		10 0 E. H. M.	PPM	Ĺ			
210.0	200.0	190.0	180.0	170.0	160.0	150.0	140.0	130.0	120.0	110.0	100.0	1 90.0	J 80.			60.0	50.0	40.0	30 	1.0 2	20.0	10.0	0.0				
	 8				14	່ [] ດີ ເວ ະ	+ იით-	- - 0 - 1	6 1	 	[_]]			[[] ~~~	 m r= -								
	199.78				166 970	148.45(148.45(137.09 136.94 136.94	130.96 128.83 128.67	128.16	113.70	97.430	97.207	77.521 77.406	76.879	73.554 67.497 67.184	56.197	50.04(51.226 50.765	37.053 36.848	35.268 34.807 31.441	30.864			0.166				

single_pulse C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorylamine¥N-Cbz,MeHVA2-1H_set.als



single pulse decoupled gated NOE C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorylamine¥N-Cbz,MeHVA2-13C_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥indometacin¥indometacin1-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥indometacin¥indometacin1-13C_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥indometacin¥indometacin2-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥indometacin¥indometacin2-13C_set.als







auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥naproxen¥naproxen-13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥antiprofileactivity¥antiprofileactivity-1H_set.als



 $auto \\ C: {\tt YUsers {\tt g} osei {\tt YDesktop {\tt f} alkyne functionalization {\tt f} antiprofile activity {\tt f} antiprofile activity {\tt -13C_set.als}}$

Me(Me(OMe	0 13a	 = _≡ ≻	20 20 00	0 141.409 139.203	234.224 129.146 128.553	7/ 124.266 122.718 116.002	108.933	97.830	77.321 77.000 76.679	73.543	60.943 56.310	22.903 29.874			DFILE COMNT DATIM OBNUC EXMOD OBFRQ OBFIN POINT FREQU SCANS ACQTM PD W1 IRNUC CTEMP SLVNT EXREF BF RGAIN	antiprofileactivity-13C_set.a auto Thu Feb 18 07:39:10 2016 13C BCM 99.45 MHz 94.00 KHz 10309.00 Hz 32768 26845.64 Hz 8000 1.2206 sec 1.7790 sec 6.50 usec 1H 22.1 c CDCL3 77.00 ppm 1.72 Hz 22
															PPM		

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥rotenone¥rotrenone1-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥rotenone¥rotrenone1-13C_set.als

(OC	¹⁹⁸ 661) ₆ Co2		о Н О 14а		157.992	147.1664	- 143.022	—— 122.331	113.402		87.839	77.321		60.540 60.375	44.968	31.323	27.586		COMNT DATIM OBNUC EXMOD OBFRQ OBSET OBFIN POINT FREQU SCANS ACQTM PD PW1 IRNUC CTEMP SLVNT EXREF BF RGAIN	auto Tue Apr 19 19:30:20 2016 13C BCM 99.45 MHz 94.00 HHz 10309.00 Hz 32768 26845.64 Hz 988 1.2206 sec 1.7790 sec 6.50 usec 1H 25.7 c CDCL3 77.00 ppm 1.02 Hz 23
210.0	200.0	190.0	180.0	170.0	160.0	150.0 14	40.0 130.	0 120	.0 110.0	100.0	90.0	80.0	70.0	60.0	50.0	40.0 30.0) 20.0	10.0 0.0	PM 	

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥rotenone¥rotenone2-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥rotenone¥rotenone2-13C_set.als

MeO MeO MeO MeO MeO HO	165.293	142.768 129.813 122.332 117.518	113.361 113.032 112.975 108.950 96.210	88.103 77.233 77.223 77.017 76.610	73.658 73.658 73.658 65.890 66.589	45.093	27.620	0.000	DATIM Wed Apr 20 09:10:10 2016 OBNUC 13C EXMOD BCM OBFRQ 99.45 MHz OBSET 94.00 KHz OBFNI 10309.00 Hz POINT 32768 FREQU 26845.64 Hz SCANS 10956 ACQTM 1.2206 sec PD 1.7790 sec PW1 6.50 usec IRNUC 1H CTEMP 27.2 c SLVNT CDCL3 EXREF 0.00 ppm BF 1.02 Hz RGAIN 23
14b	Ċo ₂ (CO) ₆								
inan-densitiensien kanterleisiendurestenetenreporteeren	ativiting believe international to provide the state of the	ughter dari paring kenstata dalapari	lekin pir norma galani norma ki norma n	where where the state of the st	ul Articologi habiyo hawi haya	indian analysis and a	Automotion	PPM	
210.0 200.0 190.0 180.0 1	170.0 160.0 150.0 1	40.0 130.0 120.	0 110.0 100.0 9	90.0 80.0	70.0 60.0	50.0 40.0	30.0 20.0 1	0.0 0.0	

~ . .

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥xanthotoxin¥xanthotoxin-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥xanthotoxin¥xanthotoxin-13C_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥colchicine¥colchicine-1H_set.als





auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥colchicine¥colchicine-13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥estradiol¥estradiol2-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥estradiol¥estradiol1-1H_set.als



DFILE estradiol3-1H_set.als 10.52OH COMNT auto DATIM Sun Oct 16 15:19:19 2016 Co₂(CO)₆ OBNUC 1H EXMOD NON Н OBFRQ 399.65 MHz OBSET 124.00 KHz 10500.00 Hz OBFIN Ĥ Ĥ POINT 16384 FREQU 7992.01 Hz HO SCANS 32 Co₂(CO)₆ ACQTM 2.0500 sec 4.9500 sec PD 6.30 usec PW1 IRNUC 1H 17c CTEMP 21.5 с CDCL3 SLVNT EXREF 0.00 ppm BF 0.42 Hz RGAIN 18 3.12 2.422.102.06 2.00 1.961.201.090.98 1.02 1.00 1.01 0.97PPM 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 0.0 1.0 111111 7.023 $6.041 \\ 5.981$ 0.000 7.261 4.795 $\begin{array}{c} \textbf{4.183}\\ \textbf{4.181}\\ \textbf{4.181}\\ \textbf{4.101}\\ \textbf{4.101}\\$ 185 883 763

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥estradiol¥estradiol3-1H_set.als

DFILE estradiol3-13C_set.als OH COMNT auto DATIM Sun Oct 16 17:51:54 2016 Co₂(CO)₆ 13C OBNUC BCM EXMOD Н OBFRQ 100.40 MHz OBSET 125.00 KHz OBFIN 10500.00 Hz Ĥ Ĥ 32768 POINT FREQU 27118.64 Hz HO SCANS 3037 Co₂(CO)₆ ACQTM 1.2083 sec PD 1.7920 sec 6.30 usec PW1 1HIRNUC 17c CTEMP 22.1 c SLVNT CDCL3 EXREF 77.00 ppm 1.02 Hz BF RGAIN 25 human was a function of the second of the se PPM 210.0 200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 199.511 149.217 134.654 133.550 126.297 125.227 123.754 95.606 94.149 10.97450.030 36£ 198 000 679 608 941 077 164 059 .260.609 .159 .402 .092 81 123 222335944

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥estradiol¥estradiol3-13C_set.als


auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥podophyllotoxin¥podophyllotoxin-13C_set.als

$\begin{array}{c} 91E \cdot 661 \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ H \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ H \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ H \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ 0 \\ \hline \\ 18a \\ \end{array}$	152.643 147.935 147.680 147.680 117.030 113.763 113.763	109.665 107.929 107.929 101.468 101.468 101.468 72.955 77.206 77.206 77.206 77.206	71.387 71.387 68.688 68.688 65.923 75.923 77.800	DFILE podophyllotoxin-13C_set.als COMNT auto DATIM Thu Jun 23 19:04:09 2016 OBNUC 13C EXMOD BCM OBFRQ 99.45 MHz OBSET 94.00 KHz OBFIN 10309.00 Hz POINT 32768 FREQU 26845.64 Hz SCANS 1162 ACQTM 1.2206 sec PD 1.7790 sec PW1 6.50 usec IRNUC 1H CTEMP 24.9 c SLVNT CDCL3 EXREF 77.00 ppm BF 0.52 Hz RGAIN 24









C:¥Users¥gosei¥Desktop¥alkyne functionalization¥eugenol¥eugenol1-13C_set.als DFILE COMNT 141.857 137.675 131.295 125.869122.708115.513 109.857 199.741 146.443 97.335 77.321 77.206 77.000 76.679 73.690 33.614 56.138 39.903 -0.017 DATIM OBNUC EXMOD OMe OBFRQ OBSET HO OBFIN POINT FREQU SCANS $(OC)_6Co_2$ ACQTM PD 19b PW1 IRNUC CTEMP SLVNT EXREF BF RGAIN PPM

eugenol1-13C_set.als

100.40 MHz

125.00 KHz

10500.00 Hz

27118.64 Hz

1.2083 sec

1.7920 sec

24.9 c CDCL3

22

77.00 ppm 0.72 Hz

6.20 usec

32768

7075

Sat Feb 20 08:49:35 2016

auto

13C

BCM

1H

auto

210.0

200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0

90.0

80.0

70.0

60.0

50.0

40.0

30.0

20.0

10.0

0.0



$(OC)_{6}Co_{2}$ $(J) = (OC)_{6}Co_{2}$ (J) = (J) = (J) (J) = (J) = (J) (J) = (J) = (J) (J) = (J) = (J) = (J) (J) = (J) =			89.592		39.849	DFILE eugenol3-13C_set.als COMNT auto DATIM Sat Apr 25 21:36:50 20 OBNUC 13C EXMOD BCM OBSET 94.00 KHz OBFIN 10309.00 Hz POINT 32768 FREQU 26845.64 Hz SCANS 1990 ACQTM 1.2206 sec PD 1.7790 sec PW1 6.50 usec IRNUC 1H CTEMP 27.7 c SLVNT CDCL3 EXREF 77.00 ppm BF 2.52 Hz RGAIN 23)15
nörd för verande under har ¹ de annet benämd kölje för berörgens gens statet anna hören syrdes her i som i som i	newsofer the second	internal scherological scherologica	alprovide advantigent of the	i birti pozzilonenentropitationeterenentropitationeterenent	Nevezyaturezek tearrzeniejszyczania szerzenie kesszerenie kesszerenie kesszerenie kesszerenie kesszeren erene	n shiph the year of the second s	
210.0 200.0 190.0 180.0 170.0 160.0	150.0 140.0 130.0	120.0 110.0 100	0.0 90.0 80.0	70.0 60.0 50.0	40.0 30.0 20.0 10.0	0.0	

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥eugenol¥eugenol3–13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥eugenol¥dec-eugenol1-1H_set.als



DFILE dec-eugenol1-13C_set.als COMNT auto DATIM Wed Apr 29 17:26:18 2015 OBNUC 13C EXMOD BCM HO OBFRQ 99.45 MHz OBSET 94.00 KHz OBFIN 10309.00 Hz MeO POINT 32768 FREQU 26845.64 Hz SCANS 2082 20 ACQTM 1.2206 sec 1.7790 sec PD 6.50 usec PW1 IRNUC 1H CTEMP 24.2 c CDCL3 SLVNT EXREF 77.00 ppm 1.02 Hz BF RGAIN 22 where the another in the second s PPM 210.0 200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 145.400 144.075 128.784127.212 $\frac{115.780}{115.130}$ $\frac{112.291}{112.291}$ 136.627 56.038 36.788 21.743675 391

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥eugenol¥dec-eugenol1-13C_set.als

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorilamine¥dec-N-Cbz,MeHVA1-1H_set.als







auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥indometacin¥dec-indometacin-1H_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥indometacin¥dec-indometacin-13C_set.als



single_pulse C:¥Users¥gosei¥Desktop¥alkyne functionalization¥naproxen¥dec-naproxen-1H_set.als



single pulse decoupled gated NOE C:¥Users¥gosei¥Desktop¥alkyne functionalization¥naproxen¥dec-naproxen-13C_set.als



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥antiprofileactivity¥dec-antiprofileactivity-1H_set.als



C:¥Use M€ M€		Desktop¥i	24			fileactivity	fdec-antip:	ofileactivit	ty-13C_set	t.als											DFILE COMNT DATIM OBNUC EXMOD OBSET OBFIN POINT FREQU SCANS ACQTM PD PW1 IRNUC CTEMP SLVNT EXREF BF RGAIN	dec-antiprofileacti auto Wed Mar 02 12:36 13C BCM 99.45 MHz 94.00 KHz 10309.00 Hz 32768 26845.64 Hz 594 1.2206 sec 1.7790 sec 6.50 usec 1H 24.3 c CDCL3 77.00 ppm 1.72 Hz 22	vity-13C_s
144 million 210.(1111-1111-1111-1111-1111-1111-1111-1111-1111	¥₩₩₩₩₩₩ 190.0	180.0	170.0	160.0 15		.0 130.c	120.0	110.0	100.0	90.0	80.0	70.0) 60.0	50.1	0 40.0	30.0	20.0	19450044 John Market	PPM 0.0			
210.0	, 200.0	130.0	100.0	110.0	100.0 10					100.0	30.0		51	,	.0.	0 40.0	30.0	20.0	10.0	0.0]		
	106 179	7 11.001			152.750	141.368	139.442 134.059 128.990 128.389	126.315 124.241 122.924	111.517 109.106 107.731		8	81.987 77.321 77.206	77.000 76.679 69.297	60.960	56.285		32.928	LE 101	TOTICT				

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥antiprofileactivity¥dec-antiprofileactivity-13C_set.

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥estradiol¥dec-estradiol2-1H_set.als





auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol¥dec-mestranol1-1H_set.als



 $\label{eq:static} auto\\ C: {\tt YUsers} {\tt g} osei {\tt YDesktop} {\tt Yalkyne functionalization} {\tt Ymestranol} {\tt Ydec-mestranol} {\tt 1-13C_set.als}$



 $auto \\ C: {\tt YUsers {\tt Ygosei {\tt YDesktop {\tt Yalkyne functionalization {\tt Ymestranol {\tt Ydec-mestranol {\tt 2-1} H_set.als}}}$



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥mestranol¥dec-mestranol2-13C_set.als



auto C:¥Users¥gosei¥個人ファイル_NMR¥岡村¥alkyne functionalization¥eugenol¥脱保護¥160714_TO-eugenol-1H_再処理.als



DFILE dec-eugenol2-13C_set.als COMNT auto DATIM Thu Jul 14 03:17:36 2016 OBNUC 13C EXMOD BCM HO OBFRQ 100.40 MHz 125.00 KHz OBSET OBFIN 10500.00 Hz POINT 32768 MeO FREQU 27118.64 Hz SCANS 2944 28 ACQTM 1.2083 sec 1.7920 sec PD PW1 6.20 usec IRNUC 1H CTEMP 26.0 c SLVNT CDCL3 EXREF 77.00 ppm BF 0.12 Hz RGAIN 25 PPM התקום המקדרות הקדרות המתקום המקדרו 210.0 200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0 90.0 80.0 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 141.273 137.774 121.679 121.119 115.554 146.122 131.385 109.651 56.06439.969 18.820 687 862 66 Ξ.

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥eugenol¥dec-eugenol2-13C_set.als

OH н Ĥ // Ĥ HO 29 PD PW1 BF 9.12 3.08 $0.96^{2.21}_{2.13}$ 2.081.37 0.99 1.091.00 1.05 1.08 1.000.93 PPM 9.0 8.0 7.0 6.0 5.0 3.0 2.0 0.0 4.0 1.0 0.772 0.000 $\begin{array}{c} 2.259\\ 6.677\\ 6.677\\ 7.735\\ 7.$ 187 178 465 453 23 408 391 378 362 349 336 321 $\begin{array}{c} 306\\ 292\\ 284\\ 276\\ 259\\ 259\\ 241\\ 216\\ 216 \end{array}$.198 **198** 5

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥estradiol¥dec–estradiol2–1H_set.als

DFILE dec-estradiol2-1H_set.als COMNT auto DATIM Fri Jul 15 18:03:07 2016 OBNUC 1H NON EXMOD OBFRQ 399.65 MHz OBSET 124.00 KHz OBFIN 10500.00 Hz POINT 16384 FREQU 7992.01 Hz SCANS 32ACQTM 2.0500 sec 4.9500 sec 6.20 usec 1HIRNUC CTEMP 24.9 c CDCL3 SLVNT EXREF 0.00 ppm 0.12 Hz RGAIN 15

DFILE dec-estradiol2-13_set.als OH COMNT auto DATIM Fri Jul 15 18:39:40 2016 OBNUC 13C EXMOD BCM н OBFRQ 100.40 MHz OBSET 125.00 KHz Ē OBFIN 10500.00 Hz // Ĥ POINT 32768 FREQU 27118.64 Hz HO SCANS 707 ACQTM 1.2083 sec 29 1.7920 sec PD 6.20 usec PW1 IRNUC 1HCTEMP 25.8 c CDCL3 SLVNT EXREF 77.00 ppm 0.82 Hz BF RGAIN 22 "We also also as the second state of the 210.0 200.0 190.0 180.0 170.0 160.0 150.0 140.0 130.0 120.0 110.0 100.0 90.0 80.0 70.0 60.0 50.0 30.0 20.0 10.0 0.0 40.0 136.226133.452125.054 120.798 113.273 151.34176.679 44.234 43.155 37.985 36.709 30.617 27.250 26.904 26.550 23.092 15.205 11.007 68.397 50.030 818

 $\label{eq:setup} \begin{array}{l} auto\\ C: {\tt YUsers {\tt Ygosei {\tt YDesktop {\tt Yalkyne functionalization {\tt Yestradiol {\tt Ydec-estradiol 2-13_set.als}} \end{array}} \\ \end{array}$

auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥Et3N complex¥Et3Ncomplex-1H_set.als









 $auto \\ C: {\tt Vsers} {\tt gose} {\tt i} {\tt Posktop} {\tt functionalization} {\tt N-CBZ-methyl homoverator} {\tt lamine} {\tt dec-N-Cbz, MeHVA2-1H_set.als} \\$



auto C:¥Users¥gosei¥Desktop¥alkyne functionalization¥N-CBZ-methyl homoveratorilamine¥dec-N-Cbz,MeHVA2-13C_set.als

